Culture Collections

New Cell Lines

We have an active programme to acquire new cell lines for our catalogue. On this page we list recent additions. You can also find these lines within the extensive Cell Line and Hybridoma collection listings.

 

XimbioNEW 

February 2020

The European Collection of Authenticated Cell Cultures (ECACC) has a variety of new cancer cell lines available, deposited by Ximbio, (Cancer Research Technology, UK) which are listed below. 

 

MCF-7

Ximbio has announced the availability of anti-oestrogen resistant breast cancer cell lines from the research of Dr Anne Lykkesfeldt at the Danish Cancer Society. These cell lines have been developed, characterised and published for a number of subtypes of parental human breast cancer cell lines including MCF-7.

 

Catalogue number Cell line name       Keywords
16022503 MCF7/164R-4 Breast cancer, fulvestrant resistance, ER alpha 
16022505 MCF7/164R-7 Breast cancer
16022510 MCF7/TAMR-8 Breast cancer, tamoxifen-resistant
16022516 MCF7/AnaR-1 Breast cancer, MCF7, Anastrozole resistance
16022518 MCF7/AnaR-3 Breast cancer, MCF7, Anastrozole resistance
16022525 MCF7/LetR-2 Breast cancer, Letrozole resistant
16022526 MCF7/LetR-3 Breast cancer, Letrozole resistant
16022528 MCF7/TAMR-4 Human, Breast, Cancer, Oestrogen receptor, Tamoxifen resistant

 

SG01

Cell line SG01 is a novel subglottic epithelial cell line which provides a unique resource for researchers to investigate subglottic diseases, such as subglottic stenosis. The subglottis is a crucial site for upper airway infection, inflammation and malignancy (specifically laryngeal cancer). It also has a crucial relationship with the lower airway in terms of infection. Previous models have included locations such as the nose or lung, however this is unlikely to fully recapitulate the subglottic airway in humans, which is a distinct respiratory niche. SG01 is an immortalised cell line that can differentiate at the air-liquid interface (ALI) in culture and demonstrates morphology of normal epithelium and cytokeratins of normal epithelium and relevant ion channel expression associated with transepithelial resistance.

 

Catalogue number Cell line name Keywords
17100230 SG01 Subglottic stenosis, cancer, inflammation, immortalised, cell line

 

Wilms’ Tumor 17.94

Genetic and epigenetic defects in the developing kidney that disrupt the normal differentiation pathway of the metanephric blastema into epithelial and stromal components in the maturing kidney gives rise to ‘Wilms’ Tumor’. These paediatric renal tumours occur at approximately 1 in 10,000 children. Most Wilms’ Tumors retain some differentiation potential, exhibiting so-called “triphasic” histology in which undifferentiated blastema can be observed, together with differentiated epithelial and stromal cells. Considerable advances in understanding the molecular pathogenesis of Wilms’ Tumor has been made, however, the cell biology of this tumour type is less well understood due to the small number of established Wilms’ Tumor cell lines. The establishment of a new Wilms’ Tumor cell line, Wilms’ Tumor 17.94, that has features expected of transformed metanephric blastemal cells, including some apparent potential for in vitro differentiation provides another model to study this disease.

 

Catalogue number Cell line name Keywords
17100502
Wilms’ Tumor 17.94 Wilms’ Tumor, cell line, anaplastic

 

HeLa EGFP-Histone H2B

Dynamic protein phosphorylation is mediated by a conserved cohort of protein kinases controlling the profound changes in cellular organization required for mitosis and cytokinesis. Many protein kinases are activated by a conserved regulatory step involving T-loop phosphorylation. Although there is considerable focus on kinase activator proteins, the importance of specific T-loop phosphatases reversing kinase activation has been underappreciated.  The protein phosphatase 6 (PP6) holoenzyme is the major T-loop phosphatase for Aurora A, an essential mitotic kinase. Loss of PP6 function by depletion of catalytic or regulatory subunits interferes with spindle formation and chromosome alignment due to increased Aurora A activity.

Two HeLa cell lines have been created to determine if PP6 catalytic activity is required for normal nuclear morphology, mitosis and cytokinesis.  These cell lines, one stably expressing EGFP-tagged histone H2B the other expressing mCherry-tagged histone H2B and EGFP-tagged alpha-tubulin, have been used in the live-cell imaging of cells revealing that PPP6C-depletion in cells does not form a bipolar spindle with normal kinetics and results in failure to efficiently align chromosomes at the metaphase plate.

 

Catalogue number Cell line name Keywords
17100529 HeLa EGFP-Histone H2B PP6 catalytic activity, EGFP, EGFP-tagged histone H2B

 

HEK293

The HEK293 GFP-WIPI1 and HEK293 GFP-WIPI2 cell lines have been developed to study autophagy by light microscopy. These stable cell line expressing GFP-tagged human WIPI1 and WIPI2 proteins are in a background of the HEK293A cell line. They are useful in studying the function of the phosphatidylinositol 3-phosphate [PtdIns(3)P] effector WIPI proteins by identifying WIPI1 and WIPI2 interacting proteins They are also useful for high throughput microscopy screens. The research areas where the function of these proteins can be studied include: autophagy and cell stress, apoptosis and programmed cell death, cancer, cell signalling & signal transduction, cellular transport, drug discovery & development, metabolism.

 

Catalogue number Cell line name Keywords
17100531 HEK293-A mRFP-ATG9 Autophagy, Cancer, Cell Signalling, Signal Transduction, Cellular Transport, Drug Discovery & Development, Metabolism
17100532 HEK293 GFP-WIPI2 Cancer, neurodegeneration, autophagy
17100533 HEK293 GFP-WIPI1 Cancer, neurodegeneration, autophagy

 

CIOV3

High grade serous ovarian cancer (HGSOC) is the most frequent histological ovarian cancer subtype. While most patients obtain a pathological complete response after first-line of chemotherapy, most of them will relapse and develop resistant fatal disease. Overall survival for women with HGSOC has not improved in the last two decades and five-year survival is less than 30%. The availability of high grade serous ovarian cancer cell line models is limited with the existing models often failing to recapitulate disease phenotypes. Three new spontaneously immortalized continuous cell lines – CIOV1, CIOV2, and CIOV3 – derived from different patients with high grade serous ovarian cancer were generated and characterised using tagged amplicon sequencing, immunohistochemistry /immunocytochemistry and shallow whole genome sequencing. Each cell line retained the genomic and pathologic characteristics of the parental tumour. All three cell lines were thoroughly characterised including their chemosensitivity to standard therapeutic drugs making them valuable models to study acquired and primary chemoresistance of HGSOC.     

Catalogue number Cell line name Keywords
17100534
CIOV1 Ovarian cancer, HGSOC
17100536 CIOV3 High grade serous ovarian cancer, TP53 mutation, BRCA1 and BRCA2 mutations, PTEN, RB1.

 

 

EBiSC and CHDINEW  

January 2020

The European Bank for induced Pluripotent Stem Cells (EBiSC) and CHDI Foundation have collaborated with Censo Biotechnologies to generate a cohort of 45 iPSC lines derived from Huntington’s disease (HD) gene-expansion carriers (HDGECs) and associated controls.

These new lines will be used to further investigate the mechanisms of HD progression and for the development of novel therapeutics and will be widely available to any interested researchers. 24 of these cell lines are currently available on our website with more coming soon. 

You can view our CHDI cell lines here.   

 

NIMP-R14NEW     

January 2020 

The NIMP-R14 cell line is a rat hybridoma, producing a monoclonal antibody IgG2b which detects neutrophils. 

Catalogue number Cell line name Keywords
18071701 NIMP-R14 Hybridoma, BALB/c mouse neutrophils, Anti-RTN4IP1 antibodies, IgG2b

 

OVPA8NEW

January 2020

High-grade serous ovarian carcinoma (HGSOC) is the most frequent histological type of ovarian cancer and the one with worst clinical prognosis. The majority of established ovarian cancer cell lines used in the research have unclear histological origin and probably do not represent HGSOC. New and reliable cellular models of HGSOC are needed. A new cell line, OVPA8, has been established and characterized.

This newly-established OVPA8 cell line shows morphologic and genetic features consistent with HGSOC, such as epithelial morphology, multiple chromosomal aberrations, TP53 mutation, BRCA1 mutation, and loss of one copy of BRCA2. The OVPA8 line has a stable STR profile. Cells are positive for EpCAM, CK19, and CD44 and have a relatively low plating efficiency, ability to form spheroids, a low migration rate, and intermediate invasiveness in Matrigel™, compared to other ovarian cancer lines. OVPA8 is sensitive to paclitaxel and resistant to cisplatin and can be a valuable preclinical model for studies on high-grade serous ovarian cancer.    

Catalogue number Cell line name Keywords
19062601 OVPA8 OVPA8, Ovarian cancer, High-grade serous ovarian cancer, HGSOC, TP53 mutation, BRCA1 mutation

 

BB2NEW

January 2020 

The monoclonal antibody BBE, alongside TYG 5 are antibodies developed to identify a 10-amino acid sequence from the major structural protein of the Saccharomyces cerevisiae Tyl virus-like particle. These two sequences have overlapping binding sites, which is useful when used in combination for double labelling in immunofluorescence or immunoelectron microscopy. BB2 does not cross-react with trypanosomal proteins.  

Catalogue number Cell line name Keywords
19072501 BB2 Anti-TY, T.brucei, virus like particle                        

 

CD1B4NEW

January 2020

The centriole is a feature of eukaryotic cells that construct cilia or flagella and is unusual in that it is one of the few organelles which exist in a single copy. In G1, a cell has two centrioles, one is mature and was generated at least two cell cycles ago. The other was produced in the previous cell cycle and is immature. Both centrioles then nucleate one procentriole each which subsequently elongate to full-length centrioles, usually in S or G2 phase.

The CD1B4 antibody has been used to specifically detect one centriole in the centriole pair, specifically the mature centriole. This epitope has been identified as a 96-kD protein termed “Cenexin”.  This antibody stains the mature centriole regardless of whether it is forming a cilium and it stains a single centriole in cells which do not possess a primary cilia. 

Catalogue number Cell line name Keywords
19072502 CD1B4

Cenexin, mature mammalian centrioles, ODF        

 

L1C6NEW

January 2020 

The African parasite Trypanosoma brucei causes African sleeping sickness in cattle and humans. Trypanosomes possess a single flagellum that is attached to their cell body via the flagellum attachment zone (FAZ). There is a complex transmembrane crosslinking of this FAZ to the paraflagellar rod (PFR) and axoneme within the flagellum. Using the L1C6 antibody (amongst others developed in the Sir William Dunn School of Pathology, Oxford) it has been shown that although the growth of both cytoplasmic FAZ filament and external paraflagellar rod (PFR) are related, their growth initiates at different time points during the cell cycle and the two structures elongate at distinct rates.

Catalogue number Cell line name Keywords
19072504 L1C6

Nucleolus, T.brucei, trypanosomes                       

 

HT29 drug resistant clonesNEW 

December 2019

Mucins are increasingly implicated as playing a role in the development of colon cancer and the resistance of tumour cells to chemotherapy. Distinct sub-populations of mucus-secreting cells have been obtained from the colon cancer cell line HT-29 after long-term treatment with the anti-cancer drugs, methotrexate (MTX) and 5-fluorouracil (5-FU), (Lesuffleur et.al, 1990, Lesuffleur et.al, 1991, respectively).

Catalogue number Cell line name Keywords
15121701 HT29-5F7 HT29-5F7, 5-fluorouracil and methotrexate-resistance, enterocytic cells, MUC1 mucin
15121702 HT29-5F12 HT29-5F12, 5-fluorouracil -resistance, enterocytic cells, MUC2 mucin
15121706 HT29-5M21 HT29-5M21, methotrexate-resistance, clone, MUC5AC and MUC5B
15121707 HT29-5M12 HT29-5M12, 5-fluorouraci, methotrexate-resistance, clone, mucin, MUC5B

 

HipSciNEW 

December 2019

A key component of the Human Induced Pluripotent Stem Cells Initiative (HipSci) is the systematic generation of iPSCs from hundreds of donors using a standardised experimental pipeline.  The iPSC lines are generated from hundreds of healthy donors, plus several cohorts of donors with inherited genetic diseases. The use of cell lines from phenotypically normal donors allows the study of how common genetic variations affect the cellular phenotypes. 

Catalogue number Cell line name Disease status
77650823 HPSI1116i-zehh_3 Rare genetic neurological disorder
77650824 HPSI1116i-zehh_4 Rare genetic neurological disorder
77650826 HPSI1016i-eoxu_2 Rare genetic neurological disorder
77650827 HPSI1016i-eoxu_6 Rare genetic neurological disorder
77650793 HPSI1016i-livl_2 Rare genetic neurological disorder
77650794 HPSI1016i-livl_5 Rare genetic neurological disorder
77650795 HPSI1016i-riwg_2 Rare genetic neurological disorder
77650796 HPSI1016i-riwg_8 Rare genetic neurological disorder

 

HipSci 

October 2019

A key component of the Human Induced Pluripotent Stem Cells Initiative (HipSci) is the systematic generation of iPSCs from hundreds of donors using a standardised experimental pipeline.  The iPSC lines are generated from hundreds of healthy donors, plus several cohorts of donors with inherited genetic diseases. The use of cell lines from phenotypically normal donors allows the study of how common genetic variations affect the cellular phenotypes. 

Catalogue number Cell line name Disease Status 

77650803

HPSI1014i-xejd_1 Normal

77650633

HPSI0616i-biln_1

Hereditary spastic paraplegia
77650800 HPSI0115i-rehy_2 Normal
77650479 HPSI0416i-mefc_1 Usher syndrome and congenital eye defects
77650639 HPSI0416i-mapx_1 Alport syndrome
77650542 HPSI0516i-oadp_5 Kabuki syndrome
77650653 HPSI0616i-giql_1 Bleeding and platelet disorders
77650858 HPSI0115i-payf_1 Normal 
77650655 HPSI0616i-gayk_3 Bleeding and platelet disorders

 

PEO1 CDDP

January 2019

The PEO1-CDDP Cell Line is an in-vitro model to understand the changes in EGF signalling after the onset of cisplatin resistance. Coupled with this change in drug sensitivity, this model also has a modified responsiveness to ligands of the erbB receptor family. This model will be helpful in studying the changes in cellular signalling after drug treatment, which are currently attracting a great deal of interest and this model will be of particular relevance when cytotoxic therapy is combined with signalling inhibitors.

Catalogue number Cell line name Keywords
16012001 PEO1-CDDP Human ovarian cancer; oestrogen receptor, drug resistance, cisplatin resistance

 

Immortalised mouse embryonic fibroblast cell lines

January 2019

The research group led by Professor Catrin Pritchard of University of Leicester, UK, has developed a series of transgenic mouse models containing knockout, inactivating or oncogenic mutations in the c-raf gene. The c-raf protein has the ability to activate the RAS/RAF/MEK/ERK signal transduction cascade. The RAS/RAF/MEK/ERK cascade is a conserved intracellular signalling pathway that plays a crucial role in controlling the ability of cells to respond to their environment. These investigators have derived immortalised mouse embryonic fibroblast cell lines from these transgenic mice.  These derived cell lines provide in vitro models to assess the role of mutations in c-Raf1 in response to apoptotic stimuli and their capability to respond to other external stimuli via the RAS/RAF/MEK/ERK intracellular signalling pathway.   

Catalogue number Cell line name Keywords

16012201

C-Raf KI D486A Knock in, oncogenic mutant
16012205 MEF Raf1 FF/FF KI Knock-in, FF/FF Raf1 (Y340F-Y341F) mutant, inactivation 
16012209 MEF RAF1 KO Knock-out, RAF1, mutant, inactivation 

 

Anti-oestrogen resistant breast cancer cell lines

January 2019

Ximbio (formerly known as Cancer Research Technology, UK) has announced the availability of anti-oestrogen resistant breast cancer cell lines from the research of Dr Anne Lykkesfeldt at the Danish Cancer Society. These cell lines have been developed, characterised and published for a number of subtypes of parental the human breast cancer cell lines MCF-7 and T47D  which  demonstrate resistance to hormone-dependent breast cancer treatments, both first-line (tamoxifen or aromatase inhibitors, anastrozole, exemestane, letrozole) and second-line treatments (fulvestrant). Both parental cell lines, MCF-7 and T47D, are dependent on oestrogen for growth and as a result the oestrogen receptor (ER) has become a key target for clinical therapies.  The anti-oestrogen resistant cell lines offer the potential for developing novel predicative biomarkers for therapy response and an improved understanding of the underlying molecular mechanisms of resistance, supporting new drug discovery. 

Catalogue number Cell line name Keywords

16022507

T47D-182R1 Breast cancer, fulvestrant resistant 

16022508

T47D-182R2

Breast cancer, fulvestrant resistant  

16022510

MCF7/TAMR-8

coming soon 
16022511 T47D/S5 Breast cancer, control for fulvestrant-resistant T47D cell lines 
16022528 MCF7/TAMR-4 coming soon
16022516 MCF7/AnaR-1 coming soon
16022518 MCF7/AnaR-3 coming soon
16022520 MCF7/ExeR-1 coming soon
16022522 MCF7/ExeR-3 coming soon
16022526 MCF7/LetR-3 coming soon

 

MEF OGG1 KO

January 2019

DNA damage generated from the byproducts of oxidative cellular metabolism have been proposed as a key factor in cancer and aging. Oxygen free radicals cause predominantly base damage in DNA with the most frequent mutagenic base lesion being 7,8-dihydro-8- oxoguanine (8-oxoG). This altered base lesion can pair with adenosine as well as cytosine residues and can lead to a greatly increased frequency of spontaneous GzC3TzA transversion mutations in repair-deficient bacterial and yeast cells. Eukaryotic cells use a specific DNA glycosylase, the product of the OGG1 gene, to remove 8-oxoG base lesions from DNA.  To assess the role of the mammalian enzyme in repair of DNA damage and prevention of carcinogenesis, homozygous ogg12y2 null mice have been generated. These animals are viable and accumulate abnormal levels of 8-oxoG in their genomes. Mouse embryonic fibroblast cell lines MEFs derived from ogg1 null mice have been established by spontaneous immortalisation in culture for the study of mutation rates in the absence of the DNA glycosylase. 

Catalogue number Cell line name Keywords
16022531 MEF OGG1 KO Mouse embryonic fibroblast, Ogg1 mutant 

 

LF2

January 2019

Embryonic stem cells provide a powerful system for the experimental analysis of mammalian development. Their genetic manipulation allows the introduction of defined modifications into the mouse germ-line, whilst in culture they constitute both an assay system for, and a potential source of, embryonic regulatory factors. Non-feeder culture conditions have been developed for the propagation of this cell line (LF2) in an undifferentiated state.    

Catalogue number Cell line name Keywords 
16022532 LF2 Mouse embryonic stem cell           

 

Human colorectal carcinoma cell lines

January 2019

HCT 116 BRCA2 -/- [42] and [46] human colorectal carcinoma cell lines were developed to study the role of BRCA2 in DNA repair and to identify additional functions of the BRCA2 gene. These cells exhibit phenotypes consistent with the loss of Rad51 foci in the presence of double-strand breaks, chromosomal rearrangements and show an elevated sensitivity to the DNA-damaging agents. They will also be useful to identify potential therapeutic agents in cancer cells with BRCA2 mutations.   

Catalogue number Cell line name Keywords 
16071901 HCT 116 BRCA2 -/- [42] BRCA2 Knock-Out, colon carcinoma model, HCT116, HCT 116 BRCA2 KO [42]          

18061301

HCT 116 BRCA2 -/- [46] BRCA2 Knock-Out, colon carcinoma model, HCT116 

 

MCF7 AREc32

January 2019

This stable human mammary MCF7-derived reporter cell line called AREc32 contains copies of the rat Glutathione-S-transferase (GST) antioxidant response element (ARE) linked to a luciferase gene. Antioxidant response elements (AREs) are transcriptional regulatory sequences involved in the activation of genes coding for a number of antioxidant proteins and enzymes that work in concert to protect tissues from oxidative insults. This cell line can be used to investigate whether anticancer drugs can induce ARE-driven gene expression. Measurement of redox-potential and antioxidant activity can also be used to monitor anti-inflammatory activity and assess water quality in aquatic environments 

Catalogue number Cell line name Keywords 
16071902 MCF7 AREc32 Cancer; drug metabolism, Antioxidant Response Element (ARE)- Luciferase           

 

N14A and N15ANEW COMING SOON 

January 2019

Pseudomyxoma peritonei (PMP) is a rare tumour of appendiceal origin which is treated primarily with cytoreductive surgery, however the morbidity is high. PMP is considered resistant to most chemotherapies and its molecular biology little understudied. Currently there is no platform for pre-clinical drug testing against this neoplasm. The development and availability of two immortalised cell lines (N14A and N15A) provides a resource fit for pre-clinical anti-tumour drug testing and oncogene activity in Pseudomyoma peritonei (PMP) tumour biology. 

Catalogue number Cell line name Keywords 
16110902 N14A            
coming soon

16110903

N15A  
coming soon

 

S_N40R2 and N_N20R1

January 2019

The tumour suppressor protein encoded by the TP53 gene is activated in response to a diverse range of cellular stresses which can lead to cell cycle arrest and cell death. This activation process is tightly controlled by an auto-regulatory feedback loop involving a direct protein-protein binding interaction between p53 and the product of the Murine Double Minute 2 (MDM2) oncogene. MDM2 is an E3 ubiquitin ligase and is a target gene of the p53 gene. MDM2 is a key negative regulator of p53 protein activity.  Once bound to p53, MDM2 inhibits p53-controlled transcriptional (RNA) activity and it also ubiquitinates the p53 protein for nuclear export and degradation by the proteosome. The reactivation of wild-type p53 (non-mutated) following exposure to small selective antagonists of the MDM2/p53 binding interaction is an attractive treatment strategy in tumours containing wild type p53. To determine how resistance to MDM2/p53 binding antagonists might develop, osteosarcoma cells, SJSA-1, and neuroblastoma cells, NGP, have been exposed to growth inhibitory concentrations of the chemically distinct MDM2 inhibitor, Nutlin-3,  and resistant cell lines have been derived, S_N40R2 and N_N20R1.  An analysis of the resistant cell strains indicates that MDM2/p53 binding antagonists will select for p53 mutations present in tumours present at a low frequency at initial diagnosis, leading to resistance cells.  Tumours and antagonist-resistant cell lines will remain responsive to other therapies, including ionising radiation. 

Catalogue number Cell line name Keywords 
17011210 S_N40R2 MDM2 inhibitor, Nutlin-3, resistance, MDM2-application 

17011212

N_N20R1 MDM2 inhibitor, Nutlin-3, resistance, MDM2-application

  

 

 

 

 

HCT 116 p300 cell lines

January 2019

The transcriptional cofactor and prototype histone acetyltransferase, p300, is involved in regulating multiple cellular processes including cell cycle regulation, proliferation, differentiation, apoptosis, DNA damage repair and adhesion properties. Somatic inactivating mutations of p300 are associated with several cancers including breast, colorectal and gastric cancers.

The research group led by Professor G Murphy, Cambridge University, has generated a series of p300-deficient clones from the colon carcinoma cell line, HCT 116 by gene targeting. A comparison of epithelial and mesenchymal-related proteins in p300-deficient and parental HCT 116 cells has shown that a number of genes involved in the interactions between cell plasma membrane and extracellular matrix that are typically involved in the process of  ‘epithelial to mesenchyme transition’ are differentially regulated at both the RNA and protein level. Cells deficient in p300 function were shown to have aggressive ‘cancer’ phenotypes, with loss of cell–cell adhesion, defects in cell–matrix adhesion and increased rates of migration through collagen and Matrigel™ matrices.

These HCT 116 p300 KO cell Lines are tools for the in-vitro study of p300 in colon carcinoma, and specifically of its role in p53-dependent apoptosis, cellular adhesion and migration. Cell lines available are p300 WT (HCT 116),  p300 KO [D10] (HCT 116), p300 KO [F5] (HCT 116), p300 KO [F2] (HCT 116) and p300 KO Rescue (HCT 116). Experiments conducted should be using at least 2 of the 3 KO cell lines. The KO clones are D10 and F5 are the most characterised. It is recommended that the parental cell line (WT) is used as the reference when using these knockout cell lines.

 

Catalogue number Cell line name Keywords 
17011201 17011201 HCT 116 p300 KO [D10] p300 Knock-Out, colon carcinoma model, HCT 116, p53-dependent apoptosis, cellular adhesion and migration
17011211 HCT 116 p300 KO Rescue p300 Knock-Out, colon carcinoma model, HCT 116, p53-dependent apoptosis, cellular adhesion and migration
17011214 HCT 116 p300 WT p300 Knock-Out,colon carcinoma model, HCT 116, p53-dependent apoptosis, cellular adhesion and migration
17011215 HCT 116 p300 KO [F2] p300 Knock-Out,colon carcinoma model, HCT 116, p53-dependent apoptosis, cellular adhesion and migration
17011216 HCT 116 p300 KO [F5] p300 Knock-Out,colon carcinoma model, HCT 116, p53-dependent apoptosis, cellular adhesion and migration

 

OX-47

January 2019

The hybridoma cell line OX-47 secretes mouse monoclonal IgG1 antibody reactive with rat CD147 membrane protein. This antibody binds to activated rat T-lymphocytes.  It reacts to all T and B cell blasts strongly. It gives weak labelling to thoracic duct lymphocytes and thymocytes. The antibody labels vascular endothelium, kidney tubules and brain capillaries.

Catalogue number Cell line name
15090220  OX-47

 

HipSci Panels

April 2017

For new users of our iPSC resource, we have composed two panels of lines from the HipSci iPSC collection that we would recommend. These lines have been selected based on their high pluritest scores, low CNV’s, comprehensively characterised assay data, and their ability to differentiate.

 

These lines are also available to order as individual lines.

 

Click here to view the panels

 

Nd ES

January 2017

A mouse embryonic stem cell (ES) line (Nd) containing a novel fluorescent reporter (VNP) to investigate the temporal dynamics of Nanog expression in mouse and to dissect the lineage potential at different Nanog expression levels. This novel reporter ES cell line allows the accurate monitoring the dynamic expression of the transcription factor Nanog in the pluripotent state. The cell line will be a valuable tool to obtain quantitative measurements of global gene expression in pluripotent mouse ES cells in different states, allowing a detailed molecular mapping of the pluripotent state.

Catalogue number Cell line name Keywords
16010601 Nd ES mouse embryonic stem cells, Nanog expression, pluripotency

 

Anti-oestrogen resistant cell lines

January 2017

Ximbio (Cancer Research Technology, UK) has announced the availability of anti-oestrogen resistant breast cancer cell lines from the research of Dr Anne Lykkesfeldt at the Danish Cancer Society. These cell lines have been developed, characterised and published for a number of subtypes of the parental human breast cancer cell lines MCF-7 and T47D, which demonstrate resistance to both first-line (tamoxifen or aromatase inhibitor) and second-line (fulvestrant) hormone-dependent breast cancer treatments. Both parental cell lines, MCF-7 and T47D, are dependent on oestrogen for growth and as a result the oestrogen receptor (ER) has become a key target for clinical therapies. The anti-oestrogen resistant cell lines have the potential to be utilised as novel models for, understanding molecular mechanisms of drug-resistance in cancer, identifying biomarkers of therapeutic response and developing new anti-cancer drugs.

 

ECACC General Cell Collection
8 items found, displaying all items.
Catalogue No. Cell Line Name Keywords
16022512 T47D/S2 Human, Breast, Cancer, Oestrogen receptor
16022509 MCF7/TAMR-7 Breast cancer, tamoxifen-resistant
16022513 T47D/TR-1 Breast carcinoma, tamoxifen resistant, oestrogen receptor
16022523 MCF7/ExeR-4 Breast cancer, Exemestane resistance
16022524 MCF7/LetR-1 Breast cancer, Letrozole resistant
16022519 MCF7/AnaR-4 Breast cancer, MCF7, Anastrozole resistance
16022501 MCF7/S0.5 Human, Breast, Cancer, Oestrogen receptor, MCF7
16022506 MCF7/182R-6 Breast cancer, fulvestrant resistant


 

CHO lines

A number of new CHO cell line variants, developed in the laboratory of Dr Mike Clark at Cambridge University have been deposited with the ECACC General Collection, by Cambridge Enterprise. These CHO cell lines express different allotypes of Fc gamma RIIA receptors on the cell surface and are useful for the investigating the binding of recombinant antibodies to human Fc receptors. Cell lines expressing human and macaque Fc receptors have been developed since these are both useful to pre-clinical research. The cell lines may be used for the measurement, by flow cytometry, of monomeric IgG binding or complexed  IgG binding to receptors. They are also used for studying the association of Fc receptor bearing cell lines with red blood cells coated with IgG. They are used in assays that include the target cell of the IgG, comparing natural IgG constant regions, mutated IgG constant regions and those with altered carbohydrate profiles. The cell lines may also be used as a release assay for batches of clinical grade antibodies since binding will be sensitive to aggregates or changes in carbohydrate composition.

Catalogue number Cell line name Keywords
15042901  CHO-K1.Cl6 CHO-K1, FcγRIIIa , Fc gamma receptor 3A, 158V, allotype, human IgG , IgG binding
15042902  CHO-K1.Cl7 CHO-K1, FcγRIIIa , Fc gamma receptor 3A, 158F, allotype, human IgG , IgG binding
15042903  CHO-K1.Cl-0204 CHO-K1, FcγRIIa , Fc gamma receptor 2A, 131R, allotype 
15042905  CHO-K1.Cl-0205 CHO-K1, FcγRIIa , Fc gamma receptor 2A, 131H, allotype, human IgG , IgG binding
15042907  CHO-K1.Cl-0206 CHO-K1, FcγRIIb , Fc gamma receptor 2b
15042908  CHO-K1.Cl-0235 CHO-K1, non-human primate FcγRIIIa , Fc gamma receptor 3A, Pan troglodytes, chimpanzee
15042909  CHO-K1.Cl-0236 / CHO-K1.Cl-0239 CHO-K1, non-human primate FcγRIIIa , Fc gamma receptor 3A, Cercocebus torquatus, red-crowned mangabey, papio anubis, olive baboon
15042910  CHO-K1.Cl-0237 CHO-K1, non-human primate FcγRIIIa , Fc gamma receptor 3A, Macaca fascicularis (Cynomolgus macaque)
15042911  CHO-K1.Cl-0238 CHO-K1, non-human primate FcγRIIIa , Fc gamma receptor 3A, Macaca mulatta (Rhesus macaque)
15042912  CHO-K1.Cl-0270 CHO-K1, non-human primate FcγRIIb , Fc gamma receptor 2b, Macaca mulatta, Rhesus macaque, Macaca fascicularis, Cynomolgus macaque

 

 

L929/A (an Adriamycin-resistant cell line)

This adriamycin-resistant cell line has been developed by exposure of the parent L929 murine fibroblast cell line (ECACC catalogue no. 85011425) to increasing concentrations of adriamycin in vitro. L929/A cells can be used in the development of novel anti-cancer treatments. The parent cell line L929 was derived from normal subcutaneous areolar adipose tissue.

Catalogue No. Cell line name Keywords
14112101 L929/A Mouse C3H/An connective tissue Adriamycin resistant

 

 

 

A Reporter Cell Line for Use in Autophagy Studies

A stable cell line expressing EGFP-tagged LC3 (rat) in background of HEK293 cell line. This reporter cell line can be used to monitor induction of autophagy after amino acid starvation or rapamycin treatment as well as autophagosome formation. Also, this cell line provides a useful tool for the study of autophagy using GFP-LC3 as a standard assay read out by both immunofluorescence and biochemical methods.

Catalogue No. Cell line name Keywords
14050801 HEK293A GFP-LC3 Human embryonic kidney, autophagy, HEK293, EGFP-rat LC3, reporter cell line, ATG8, microtubule-associated protein 1 light chain 3 beta (MAP1LC3B)

 

 

HeLa-Mitotrap ‘Knock-sideways’ Cell Lines for Investigating Protein Function

Two new HeLa-Mitotrap cell lines, which can be used to determine the function of a protein, by rapidly inactivating the protein of interest through rapamycin induced rerouting to the mitochondria, a ‘knock sideways’ approach, are now available from ECACC. This method of protein inactivation, which relocates proteins away from their site of action rather than destroying them, is more rapid than knockout or knock down strategies.

 

 

Catalogue No.

Cell line name

                     
Keywords
15042201 HeLa-Mitrotrap Human cervix carcinoma, knocksideways, rapid protein inactivation by rerouting to mitochondria for functional studies, genetically modified
15042203 HeLa-Mitrotrap Ap1g1-FKBP Human cervix carcinoma, knocksideways, rapid protein inactivation by rerouting to mitochondria for functional studies, adaptor protein (Ap1g1), genetically modified

 

 

ULK cell lines for autophagy research

A series of mouse embryonic fibroblasts with different capability for  uncoordinated (Unc)-51-like kinase 1 and 2 (ULK1 and ULK2) activity, which are known to play a critical role during the activation of autophagy, are now available from PHE’s European Collection of Authenticated Cell Cultures (ECACC).  Autophagy is the mechanism by which a cell degrades unnecessary or dysfunctional cellular components and has been implicated in several medical scenarios such as cancer, neurodegeneration and immunity related disorders.  The cell lines were deposited by Dr Sharon Tooze of Cancer Research UK.

 

Catalogue No.

Cell line name

ULK 1 and 2 status        

Immortalisation method             

14050808

ULK1/2 WT MEF (SIM)

Wild type

Spontaneously immortalised

14050804

ULK1/2 WT MEF (SV40)

Wild type

SV40-immortalised

14050806

ULK1 KO MEF (SIM)

ULK1 knock-out

Spontaneously immortalised

14050807

ULK1 KO MEF (SV40)

ULK1 knock-out

SV40-immortalised

14050810

ULK2 KO MEF (SIM)

ULK2 knock-out

Spontaneously immortalised

14050805

ULK2 KO MEF (SV40)

ULK2 knock-out

SV40-immortalised

14050803

MEF Ulk1 -/- Ulk2 -/- (DKO) (SIM)

Double knock-out

Spontaneously immortalised

14050802

MEF Ulk1 -/- Ulk2 -/- (DKO) (SV40)

Double knock-out

SV40-immortalised

 

 

 

 

77650633

 

Kabuki syndrome

 

77650827

 

HT29-5M21, methotrexate-resistance, clone, MUC5AC and MUC5B.

Back to top
Copyright © Public Health England.

Please confirm your country of origin from the list below.